These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 22325168)

  • 1. Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experience.
    Sprakes MB; Ford AC; Warren L; Greer D; Hamlin J
    J Crohns Colitis; 2012 Mar; 6(2):143-53. PubMed ID: 22325168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience.
    Sprakes MB; Hamlin PJ; Warren L; Greer D; Ford AC
    J Crohns Colitis; 2011 Aug; 5(4):324-31. PubMed ID: 21683302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of methotrexate therapy for refractory Crohn's disease: a large single-centre experience.
    Suares NC; Hamlin PJ; Greer DP; Warren L; Clark T; Ford AC
    Aliment Pharmacol Ther; 2012 Jan; 35(2):284-91. PubMed ID: 22112005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensification of infliximab therapy in Crohn's disease: efficacy and safety.
    M Chaparro ; Martínez-Montiel P; Van Domselaar M; Bermejo F; Pérez-Calle JL; Casis B; Román AL; Algaba A; Maté J; Gisbert JP
    J Crohns Colitis; 2012 Feb; 6(1):62-7. PubMed ID: 22261529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of infliximab in pediatric Crohn's disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy.
    Ruemmele FM; Lachaux A; Cézard JP; Morali A; Maurage C; Giniès JL; Viola S; Goulet O; Lamireau T; Scaillon M; Breton A; Sarles J;
    Inflamm Bowel Dis; 2009 Mar; 15(3):388-94. PubMed ID: 19023899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical experience with adalimumab in a multicenter Swiss cohort of patients with Crohn's disease.
    Nichita C; Stelle M; Vavricka S; El-Wafa Ali A; Ballabeni P; de Saussure P; Straumann A; Rogler G; Michetti P
    Digestion; 2010; 81(2):78-85. PubMed ID: 20093835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped.
    Louis E; Mary JY; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Dupas JL; Pillant H; Picon L; Veyrac M; Flamant M; Savoye G; Jian R; Devos M; Porcher R; Paintaud G; Piver E; Colombel JF; Lemann M;
    Gastroenterology; 2012 Jan; 142(1):63-70.e5; quiz e31. PubMed ID: 21945953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease.
    Rosh JR; Lerer T; Markowitz J; Goli SR; Mamula P; Noe JD; Pfefferkorn MD; Kelleher KT; Griffiths AM; Kugathasan S; Keljo D; Oliva-Hemker M; Crandall W; Carvalho RS; Mack DR; Hyams JS
    Am J Gastroenterol; 2009 Dec; 104(12):3042-9. PubMed ID: 19724267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk Factors for Rescue Therapy in Crohn's Patients Maintained on Infliximab After Withdrawal of the Immunomodulator: A Long-Term Follow-Up.
    Fischer M; Campbell SC; Calley CSJ; Helper DJ; Chiorean MV; Fadda HM
    Dig Dis Sci; 2017 Nov; 62(11):3131-3137. PubMed ID: 28986660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Frequency and possible reasons for the loss of response to biological therapy in Crohn's disease after a one-year treatment period].
    Molnár T; Farkas K; Nyári T; Szepes Z; Nagy F; Kiss T; Wittmann T
    Orv Hetil; 2011 Jun; 152(24):951-7. PubMed ID: 21609921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study.
    Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    J Crohns Colitis; 2014 Nov; 8(11):1454-63. PubMed ID: 24947334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease.
    Bortlik M; Duricova D; Malickova K; Machkova N; Bouzkova E; Hrdlicka L; Komarek A; Lukas M
    J Crohns Colitis; 2013 Oct; 7(9):736-43. PubMed ID: 23200919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study.
    Jahnsen J; Detlie TE; Vatn S; Ricanek P
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():45-52. PubMed ID: 26395534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study.
    Zorzi F; Zuzzi S; Onali S; Calabrese E; Condino G; Petruzziello C; Ascolani M; Pallone F; Biancone L
    Aliment Pharmacol Ther; 2012 Jun; 35(12):1397-407. PubMed ID: 22519466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is there a benefit from the concomitant use of immunosupression with anti-TNF in Crohn's disease; heads or tails?
    Lakatos PL
    Rev Recent Clin Trials; 2009 Sep; 4(3):152-8. PubMed ID: 20028325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab as a bridge to remission maintained by antimetabolite therapy in Crohn's disease: A retrospective study.
    Chauvin A; Le Thuaut A; Belhassan M; Le Baleur Y; Mesli F; Bastuji-Garin S; Delchier JC; Amiot A
    Dig Liver Dis; 2014 Aug; 46(8):695-700. PubMed ID: 24893686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Anti-TNF therapy in treatment of luminal Crohn's disease].
    Marko B; Prka L
    Acta Med Croatica; 2013 Apr; 67(2):179-89. PubMed ID: 24471301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease.
    af Björkesten CG; Nieminen U; Sipponen T; Turunen U; Arkkila P; Färkkilä M
    Scand J Gastroenterol; 2013 May; 48(5):543-51. PubMed ID: 23477356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial.
    Panaccione R; Loftus EV; Binion D; McHugh K; Alam S; Chen N; Guerette B; Mulani P; Chao J
    Can J Gastroenterol; 2011 Aug; 25(8):419-25. PubMed ID: 21912766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.